Parkinnova therapeutics BV

Parkinnova Therapeutics B.V. is a pioneering spin-off company from the University of Amsterdam, specializing in the development of innovative treatments for Parkinson’s disease. Established by molecular neuroscience experts prof. dr. Marten P. Smidt and dr. Lars P. van der Heide, Parkinnova leverages decades of collective expertise and fundamental insights into the pathophysiology of Parkinson’s disease and the dopaminergic cells involved in the disorder.

Parkinnova is developing a groundbreaking dual-action treatment approach for Parkinson’s disease, centered on the inhibition of PDE11A, a unique enzyme enriched in the dopamine cells affected by the disorder. This innovative approach aims to deliver not only a novel mechanism of action for symptom alleviation but also to slow or halt disease progression by providing neuroprotective effects. This targeted strategy promises to revolutionize the management of Parkinson’s disease, offering patients a more sustainable and effective treatment option, ultimately enhancing their quality of life.